

Major Depressive Disorder and Functional Impairment: Key Concepts for Enhancing Patient Outcomes

This supplement to *The American Journal of Managed Care* reviews the unique nature of the functional impairment that is associated with major depressive disorder, with special focus on the importance of achieving early, quality disease remission and the need for long-term maintenance therapy.

■ Participating Faculty

Kathleen M. Dorries, PhD

Senior Medical Writer
Advogent
Wayne, New Jersey

Jean Endicott, PhD

Professor of Clinical Psychology
Department of Psychiatry
Columbia University
New York, New York

Wayne Katon, MD

Professor, Vice Chair,
Director of Division of
Health Services and
Psychiatric Epidemiology
University of Washington
Medical School
Seattle, Washington

Michael S. Klinkman, MD, MS

Associate Professor
Departments of Family Medicine
and Psychiatry
University of Michigan Health
System
Ann Arbor, Michigan

George I. Papakostas, MD

Director, Treatment-Resistant
Depression Studies
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

■ Faculty Disclosures

These participants report relationships with the following organizations:

Kathleen M. Dorries, PhD Employee of Advogent, which received funding for the supplement from Pfizer Inc, formerly Wyeth Research

Jean Endicott, PhD *Consultant/Advisory Board Member:* Cyberonics, Lilly, Wyeth Research; *Honoraria:* Lilly, Wyeth Research

Wayne Katon, MD *Advisory Board Member:* Lilly; *Honoraria:* Forest, Lilly, Pfizer, Wyeth

Michael S. Klinkman, MD, MS *Scientific Advisory Board/Honoraria:* Wyeth Pharmaceuticals; *Medical Advisory Board:* Cielo MedSolutions, LLC

George I. Papakostas, MD *Consultant/Board Member:* AstraZeneca, Lilly, Otsuka, Pamlab, Wyeth; *Honoraria:* AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Lundbeck, Otsuka, Pfizer, Wyeth; *Lecturer:* AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Otsuka, Pfizer

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

Major Depressive Disorder and Functional Impairment: Key Concepts for Enhancing Patient Outcomes

Funding

This supplement has been supported by funding from Pfizer Inc, formerly Wyeth Research.

This supplement was derived from a roundtable discussion, "Functional Outcomes: Key Endpoints in the Management of Major Depressive Disorder," which took place on April 29, 2009, and was sponsored by an unrestricted educational grant from Pfizer Inc, formerly Wyeth Research, Collegeville, Pennsylvania, awarded to the Advogent Group, Inc.



The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.